Project: Development of a companion diagnostic for use with SOL101 in the treatment of Fragile X Syndrome
| Acronym | FXSFIX (Reference Number: 10197) |
| Duration | 01/03/2016 - 01/09/2018 |
| Project Topic | FXSFIX will deliver a diagnostic biomarker for use with SOL101, a clinical candidate drug for the treatment of Fragile X Syndrome (FXS). SOL101 is a first in class drug for FXS which is an orphan disease with no current clinically available treatments. SOL101 is an inhibitor of p70 S6 kinase 1 (S6K1), a protein recently shown to have utility in the control of aberrant protein production which is a phenotypic hallmark of FXS and will aim to reverse the symptoms suffered by patients. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 4 |